FI120397B - Uudet sulfonamidit - Google Patents

Uudet sulfonamidit Download PDF

Info

Publication number
FI120397B
FI120397B FI972628A FI972628A FI120397B FI 120397 B FI120397 B FI 120397B FI 972628 A FI972628 A FI 972628A FI 972628 A FI972628 A FI 972628A FI 120397 B FI120397 B FI 120397B
Authority
FI
Finland
Prior art keywords
methoxy
phenoxy
pyridin
pyrimidin
tetrazol
Prior art date
Application number
FI972628A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI972628L (fi
FI972628A0 (fi
Inventor
Werner Neidhart
Henri Ramuz
Volker Breu
Jean-Marie Cassal
Martine Clozel
Georges Hirth
Bernd-Michael Loeffler
Marcel Mueller
Kaspar Burri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI972628L publication Critical patent/FI972628L/fi
Publication of FI972628A0 publication Critical patent/FI972628A0/fi
Application granted granted Critical
Publication of FI120397B publication Critical patent/FI120397B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Lubricants (AREA)
  • Surgical Instruments (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI972628A 1994-12-20 1997-06-18 Uudet sulfonamidit FI120397B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CH383794 1994-12-20
CH383794 1994-12-20
CH241995 1995-08-24
CH241995 1995-08-24
PCT/EP1995/004843 WO1996019459A1 (en) 1994-12-20 1995-12-08 Novel sulfonamides
EP9504843 1995-12-08

Publications (3)

Publication Number Publication Date
FI972628L FI972628L (fi) 1997-06-18
FI972628A0 FI972628A0 (fi) 1997-06-18
FI120397B true FI120397B (fi) 2009-10-15

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972628A FI120397B (fi) 1994-12-20 1997-06-18 Uudet sulfonamidit

Country Status (25)

Country Link
US (1) US6004965A (cs)
EP (1) EP0799209B1 (cs)
JP (1) JP2989014B2 (cs)
KR (1) KR100445085B1 (cs)
CN (1) CN1098254C (cs)
AT (1) ATE246681T1 (cs)
AU (1) AU701767B2 (cs)
BR (1) BR9510104A (cs)
CA (1) CA2208018C (cs)
CY (1) CY2495B1 (cs)
CZ (1) CZ287916B6 (cs)
DE (1) DE69531457T2 (cs)
DK (1) DK0799209T3 (cs)
ES (1) ES2203649T3 (cs)
FI (1) FI120397B (cs)
HU (1) HU228619B1 (cs)
IL (1) IL116385A (cs)
MA (1) MA23744A1 (cs)
MY (1) MY131126A (cs)
NO (1) NO316645B1 (cs)
NZ (1) NZ297797A (cs)
PT (1) PT799209E (cs)
SA (1) SA95160421B1 (cs)
TW (1) TW313568B (cs)
WO (1) WO1996019459A1 (cs)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP0949931B1 (en) 1996-12-06 2008-08-27 Amgen Inc., Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
ES2221696T3 (es) * 1997-08-19 2005-01-01 F. Hoffmann-La Roche Ag Procedimiento para la preparacion de piridinas 2,5.disustituidas.
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ES2252894T3 (es) * 1998-08-10 2006-05-16 F. Hoffmann-La Roche Ag Procedimiento para la preparacion de 2-carbamoil piridinas.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
HK1042251B (en) * 1999-01-13 2012-07-20 Bayer Healthcare Llc Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
AU775194B2 (en) 1999-09-03 2004-07-22 Actelion Pharmaceuticals Ltd Bis-sulfonamides
WO2001046156A1 (en) * 1999-12-22 2001-06-28 Actelion Pharmaceuticals Ltd. Butyne diol derivatives
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JP4245130B2 (ja) * 2000-12-18 2009-03-25 アクテリオン ファーマシューティカルズ リミテッド 新規なスルファミド類
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ES2378670T3 (es) 2002-02-11 2012-04-16 Bayer Healthcare, Llc Aril ureas como inhibidores de cinasas
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
JP4769460B2 (ja) 2002-12-02 2011-09-07 アクテリオン ファーマシューティカルズ リミテッド 新規スルファミド類
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
JP4860474B2 (ja) 2003-05-20 2012-01-25 バイエル、ファーマシューテイカルズ、コーポレイション Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素
AU2004259760B9 (en) 2003-07-23 2011-02-03 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
SG153831A1 (en) 2004-03-17 2009-07-29 Novartis Ag Use of renin inhibitors in therapy
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
WO2008009435A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
KR101503937B1 (ko) 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
EP2478922B1 (en) 2007-02-19 2017-02-01 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
HRP20120476T1 (hr) 2007-11-05 2012-06-30 Novartis Ag Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza
ES2375527T3 (es) 2007-12-03 2012-03-01 Novartis Ag Derivados 1,2-disustituidos-4-bencilamino-pirrolidina como inhibidores cetp útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
EA201101621A1 (ru) 2009-05-15 2012-05-30 Новартис Аг Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
BRPI1015069A2 (pt) 2009-05-28 2019-09-24 Novartis Ag compostos derivados de aminobutíricos substituidos como inibidores de neprilisina, uso dos mesmos, composição farmacêutica, combinação e método para inibição de atividade endopeptidase neutra.
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
EP2507234B1 (en) 2009-11-30 2014-03-12 Novartis AG Imidazole derivatives as aldosterone synthase inhibitors
NZ602909A (en) 2010-04-15 2015-01-30 Marinepolymer Tech Inc Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
JP6144254B2 (ja) 2011-04-15 2017-06-07 マリン ポリマー テクノロジーズ，インコーポレーテッド ポリ−ｎ−アセチルグルコサミンナノファイバを用いた疾患の治療
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
DK2956464T3 (en) 2013-02-14 2018-07-16 Novartis Ag Substituted bisphenyl-butane phosphonic acid derivatives as NEP (neutral endopeptidase) inhibitors
UY35671A (es) 2013-07-25 2015-02-27 Novartis Ag Bioconjugados de polipéptidos de apelina sintética
PE20160878A1 (es) 2013-07-25 2016-09-08 Novartis Ag Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
JP2018507187A (ja) 2015-01-23 2018-03-15 ノバルティス アーゲー 改善された半減期を有する合成アペリン脂肪酸コンジュゲート
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 新的經吡啶及經嘧啶取代之三ｕｖ吸收劑
CN116456984A (zh) 2020-11-05 2023-07-18 爱杜西亚药品有限公司 克拉生坦二钠盐的稳定结晶水合物
EP4582086A3 (en) 2021-12-17 2025-07-23 Idorsia Pharmaceuticals Ltd Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (cs) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (cs) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
PT799209E (pt) 2003-12-31
NO316645B1 (no) 2004-03-22
ES2203649T3 (es) 2004-04-16
AU4304196A (en) 1996-07-10
DE69531457D1 (en) 2003-09-11
CN1098254C (zh) 2003-01-08
BR9510104A (pt) 1997-11-25
CZ187497A3 (en) 1997-10-15
SA95160421B1 (ar) 2006-05-01
NZ297797A (en) 1999-10-28
HUT77884A (hu) 1998-09-28
CA2208018C (en) 2007-03-27
NO972538D0 (no) 1997-06-04
IL116385A (en) 2000-07-16
EP0799209A1 (en) 1997-10-08
IL116385A0 (en) 1996-03-31
FI972628L (fi) 1997-06-18
JP2989014B2 (ja) 1999-12-13
MX9704587A (es) 1998-07-31
MY131126A (en) 2007-07-31
NO972538L (no) 1997-06-04
DK0799209T3 (da) 2003-11-24
ATE246681T1 (de) 2003-08-15
JPH10509182A (ja) 1998-09-08
US6004965A (en) 1999-12-21
CZ287916B6 (cs) 2001-03-14
MA23744A1 (fr) 1996-07-01
HK1001973A1 (en) 1998-07-24
CA2208018A1 (en) 1996-06-27
DE69531457T2 (de) 2004-06-24
AU701767B2 (en) 1999-02-04
WO1996019459A1 (en) 1996-06-27
CN1170407A (zh) 1998-01-14
KR100445085B1 (ko) 2004-10-14
EP0799209B1 (en) 2003-08-06
HU228619B1 (en) 2013-04-29
TW313568B (cs) 1997-08-21
FI972628A0 (fi) 1997-06-18
CY2495B1 (en) 2005-09-02

Similar Documents

Publication Publication Date Title
FI120397B (fi) Uudet sulfonamidit
FI112944B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten sulfonyyliaminopyrimidiinijohdannaisten valmistamiseksi
KR100819668B1 (ko) 신규한 피리미딘-설퍼아마이드
KR100478797B1 (ko) 엔도텔린 수용체 길항제로서의 4-(헤테로사이클릴설폰아미도)-6-메톡시-5-(2-메톡시페녹시)-2-페닐- 또는 -피리딜-피리미딘
EP1137642A1 (en) Bis-sulfonamides
US7091201B2 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
CZ289920B6 (cs) Derivát sulfonamidu, způsob jeho přípravy, farmaceutický prostředek, který ho obsahuje a meziprodukt pro jeho přípravu
WO2001081335A1 (en) Pyrimidine-sulfonamides having endothelin-antagonist activity
JPH09110840A (ja) 新規なスルホニルアミノピリミジン類
RU2151767C1 (ru) Сульфонамиды и фармацевтическая композиция
WO2002083650A1 (en) Novel sulfonylamino-pyrimidines
NO327220B1 (no) Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser
MXPA97004587A (es) Sulfonamidas novedosas
PL185692B1 (pl) Nowe sulfonamidy, sposób ich wytwarzania oraz zawierające je preparaty farmaceutyczne
HK1001973B (en) Sulfonamides
EP1322624B1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120397

Country of ref document: FI

MA Patent expired